1. Cancer Stat Facts: Leukemia – Acute Myeloid Leukemia (AML). National Cancer Institute. https://seer.
cancer.gov/statfacts/html/amyl.html. Accessed January 9, 2020.
2. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment
patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol.
2015;94:1127–1138.
3. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol.
2011;152:524–542.
4. Miyazaki y, Honda S, Sakura T, et al. Clinical features and prognosis of unselected patients with AML and
RAEB-2 Japan Adult Leukemia Study Group CS-07 study. Blood. 2016;128(22):5164. https://ashpublications.
org/blood/article/128/22/5164/99570/Clinical-Features-and-Prognosis-of-Unselected. Accessed January 9, 2020.
5. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol. 2012;96:186–193.
6. Erba HP. Prognostic factors in elderly patients with AML and the implications for treatment. Hematology
Am Soc Hematol Educ Program. 2007;2007(1):420–428.
7. Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly:
mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica.
2018;103:1853–1861.
8. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
9. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study.
Haematologica. 2012;97:1916–1924.
10. Bertoli S, Tavitian S, Huynh A, et al. Improved outcome for AML patients over the years 2000–2014.
159
New drugs for elderly patients with AML
Blood Cancer J. 2017;7:635–643.
11. National Comprehensive Cancer Network. NCCN clinical practice guideline version 2.2020 acute myeloid
leukemia (age > 18 years). https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed January
9, 2020.
12. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with
or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in
patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.
13. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with
conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
J Clin Oncol. 2010;28:562–569.
14. Swerdlow SH, Campo E, Harris NL, et al. eds. WHO classification of tumors of haematopoietic and
lymphoid tissues. 4th rev ed. Lyon, France: IARC; 2017.
15. Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML):
revised Canadian consensus guidelines. Am J Blood Res. 2017;7:30–40.
16. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacytidine vs conventional care
regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
17. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial
of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol.
2012;30:2670–2677.
18. Fenaux P, Gobbi M, Kropf PL, et al. Results of ASTRAL-1 study, a phase 3 randomized trial of
guadecitabine vs treatment choice in treatment naïve acute myeloid leukemia not eligible for intensive
chemotherapy. In: Proceedings from European Hematology Association (EHA) 24th Annual Meeting; Jun
15, 2019; Amsterdam, NL. Oral abstract S879.
19. Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine
versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol.
2014;32:1919–1926.
20. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older
patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin
Oncol. 2012;30:2492–2499.
21. Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients
with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled double-blind,
multinational, phase 3 study. Lancet Oncol. 2015;16:1025–1036.
22. Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14:3819–3830.
23. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/
daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239–3246.
24. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus
conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid
leukemia. J Clin Oncol. 2018;36:2684–2692.
25. Pigneux A, Béné MC, Salmi LR, et al. Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007
FILO Trial. J Clin Oncol. 2018;36:3203–3210.
26. Tischer J, Gergely F. Anti-mitotic therapies in cancer. J Cell Biol. 2019;218:10–11.
27. Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage I of a phase 2 study assessing the efficacy, safety,
and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute
myeloid leukemia. Cancer. 2013;119(14):2611–2619.
28. Goroshchuk O, Kolosenko I, Vidarsdottir L, et al. Polo-like kinases and acute leukemia. Oncogene. 2019
Jan;38(1):1–16.
29. Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without
volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426–1433.
30. Döhner H, Symeonidis A, Sanz MA, et al. Phase III randomized trial of volasertib plus low-dose cytarabine
(LDAC) vs placebo plus LDAC in patients aged >65 years with previously untreated AML, ineligible
for intensive therapy. In: Proceedings from 21th European Hematology Association; 9–12 June, 2016;
Copenhagen, Denmark.
31. Naoe T. Mechanism-based therapy for leukemia: a lesson from ATRA therapy. Nagoya J Med Sci.
2001;64:103–108.
160
Tomoki Naoe
32. de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: A paradigm for oncoprotein-targeted cure.
Cancer Cell. 2017;32(5):552–560.
33. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or =60 years) with newly
diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA
and idarubicin (AIDA) protocols. Leukemia. 2003;17:1085–1090.
34. Sanz MA, Vellenga E, Rayón C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the
treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104:3490–3493.
35. Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19:230–233.
36. Ono T, Takeshita A, Kishimoto Y, et al. Long-term outcome and prognostic factors of elderly patients with
acute promyelocytic leukemia. Cancer Sci. 2012;103:1974–1978.
37. Zhang Y, Zhang Z, Li J, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of
elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013;119:115–125.
38. Lengfelder E, Hanfstein B, Haferlach C, et a. Outcome of elderly patients with acute promyelocytic
leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol. 2013;92:41–52.
39. Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated
with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275–1283.
40. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic
leukemia. N Engl J Med. 2013;369:111–121.
41. Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog
signaling in cancer stem cells. Clin Cancer Res. 2015;21(3):505–13.
42. Terao T, Minami Y. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment. Cells.
2019;8: E312.
43. Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without
glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Leukemia. 2019;33:379–389.
44. Merino D, Kelly GL, Lessene G, et al. BH3-Mimetic drugs: Blazing the trail for new cancer medicines.
Cancer Cell. 2018;34:879–891.
45. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatmentnaive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
46. Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol.
2013;97:165–174.
47. Welch JS, Link DC. Genomics of AML: clinical applications of next-generation sequencing. Hematology
Am Soc Hematol Educ Program. 2011;2011:30–35.
48. Blumenthal GM, Pazdur R. Approvals in 2018: a histology-agnostic new molecular entity, novel end points
and real-time review. Nat Rev Clin Oncol. 2019;16:139–141.
49. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci. 2004;61:2932–2938.
50. Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3
mutation. Int J Hematol. 2006;83:301–308.
51. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia
with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
52. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol.
2017;18:1061–1075.
53. Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies.
Leukemia. 2017;31:272–281.
54. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid
leukemia. Blood. 2017;130(6):722–731.
55. Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins,
induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia.
2019;33:2575–2584.
56. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed
or refractory AML. N Engl J Med. 2018;378:2386–2398.
...
論文の公開元へ
